Post-earnings recap
Reported
Thu, Apr 29, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss per share of $0.34, which was slightly below expectations. The stock reacted negatively, declining by 2.08% following the earnings announcement. The lack of revenue and guidance may contribute to investor uncertainty moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.34 | N/A | -3.03% |
| Revenue | $0 | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.